Chondrocytes are the specialised cells that comprise living cartilage, responsible for producing and maintaining the extracellular matrix of collagen and proteoglycans. These cells reside within small spaces called lacunae and secrete the complex molecules that give cartilage its unique mechanical properties—resilience, load-bearing capacity, and smooth articulation. Unlike many cell types, chondrocytes are avascular, meaning cartilage receives no direct blood supply; nutrients diffuse through the matrix, making metabolic support challenging. Native chondrocytes are notoriously difficult to grow in culture; prolonged expansion often triggers dedifferentiation, where cells lose their cartilage-producing phenotype. Stem-cell-derived chondrocytes bypass this limitation by generating fresh cells with intact function. For joint repair protocols, these engineered chondrocytes are seeded into scaffolds or combined with growth factors to promote cartilage regeneration. Allogeneic forms—sourced from cadaveric tissue or expanded from donated stem cells—offer off-the-shelf convenience but require immunosuppression or immune tolerance. Current clinical applications focus on small cartilage defects in the knee; scaling to large surface areas and ensuring durability over decades of joint use remain significant challenges under continued investigation.
Conditions where Chondrocytes are explored
Evidence & approval status
For most conditions, therapy using Chondrocytes is investigational — not an approved cure — outside established blood/immune transplantation. Check the published evidence and whether a registered trial is open with our candidacy check and cell-type selector.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational information only. Chondrocytes protocols for most conditions remain investigational; outcomes vary by patient. Not medical advice.